Skip to main content

Table 1 Clinical characteristics stratified by the timing of selective immunosuppressive therapy initiation (SIT)

From: Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Covariate ≤ 10 days of onset
N = 44
> 10 days of onset
N = 40
P
ICI type, No. (%)    0.687
Anti-CTLA-4 monotherapy 11 (25) 10 (25)  
Anti-PD-1/L1 monotherapy 19 (43) 14 (35)  
Combination 14 (32) 16 (40)  
Diarrhea grade, No. (%)    0.668
1–2 8 (18) 6 (15)  
3 28 (64) 29 (73)  
4 8 (18) 5 (13)  
Colitis grade, No. (%)    0.603
1–2 24 (56) 22 (55)  
3 16 (37) 17 (43)  
4 3 (7) 1 (3)  
Endoscopic features, No. (%)    0.739
Ulcer 13 (42) 17 (52)  
Non-ulcerative inflammation 12 (39) 11 (33)  
Normal 6 (19) 5 (15)  
High-risk endoscopic features initially, No. (%)a 17 (55) 23 (70) 0.302
Overall duration of steroids, mean days (SD) 64 (38) 82 (51) 0.092
Duration of hospitalization, mean days (SD) 10 (8) 12 (8) 0.321
Duration of symptoms, mean days (SD) 25 (32) 50 (40) 0.002
Follow-up duration, mean months (SD) 5 (3) 4 (3) 0.875
Number of steroids tapering attempts, median (IQR) 1 (1–4) 2 (1–4) < 0.001
Multiple hospitalization, No. (%) 13 (30) 22 (55) 0.026
Failed steroid tapering after SIT, No. (%)b 9 (23) 19 (49) 0.033
Recurrent IMC, No. (%) 8 (18) 8 (20) 1.000
Infectious adverse events, No. (%) 16 (36) 9 (23) 0.233
  1. aHigh-risk features are ulcers deeper than 2 mm or wider than 1 cm, and extensive endoscopic inflammation involving the colon proximal to the splenic flexure
  2. bAvailable for the 79 patients who received steroids
  3. Abbreviation: SIT, selective immunosuppressive therapy